BioCentury | Oct 27, 2020

Tumor profiling play Caris to grow biopharma partnerships with $310M round

With a newly raised $310 million in combined equity and debt, Caris plans to scale up its tumor profiling business and expand its biopharma partnerships.  The round, which includes Caris Life Sciences Inc.’s first equity...
BioCentury | Sep 4, 2020
Product Development

Rain to advance growing precision oncology pipeline with $63M series B

A crossover-heavy $63 million series B round will provide Rain with enough money to bring what it says is its new lead program — a newly licensed cancer therapy from Daiichi Sankyo — through clinical proof of...
BioCentury | Jul 23, 2020

Elevation debuts with tumor-agnostic mAb in Phase II

...development in 2018 after it failed to improve progression-free survival in the SHERLOC study for HRG-positive...
...factor receptor 2 HER3 (ERBB3; EGFR3) - Erb-b2 receptor tyrosine kinase 3 HRG (HPRG) - Histidine-rich glycoprotein...
BioCentury | Oct 29, 2019
Company News

Oct. 28 Company Quick Takes: MOR106 dropped in atopic dermatitis; plus Blueprint, Merus, Gilead-Glympse, Heron and GSK

Galapagos, MorphoSys, Novartis discontinue atopic dermatitis program With an interim analysis indicating futility of the Phase II IGUANA trial, MorphoSys AG (Xetra:MOR; NASDAQ:MOR), Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and Novartis AG (NYSE:NVS; SIX:NOVN) terminated development of...
BioCentury | Jun 28, 2019
Product Development

Why tissue-agnostic drug development needs NGS to go mainstream

Next-generation sequencing is emerging as the rate-limiting factor for how fast and broadly tissue-agnostic drug development will take off in drug development. By engaging community oncologists, some companies hope to spread the word and enable...
BioCentury | Oct 3, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Sep 21, 2018
Tools & Techniques

Precision for pancreatic cancer

Real-time sequencing and organoid-based screens in pancreatic cancer could place new targets and biomarkers in the hands of drug developers looking for ways to side-step KRAS, a gene mutated in 90% of patients. Because KRAS...
BioCentury | Jun 16, 2018
Product Development

NSCLC disrupted

This year’s ASCO made clear that PD-1 inhibitors have supplanted chemotherapy as standard of care in first-line metastatic NSCLC. The unanticipated consequence is the knock-on effects for companies with studies under way in both first-...
BioCentury | May 24, 2018
Product R&D

Bias-less bispecifics

Taking a leaf from the small molecule playbook, cancer play Merus N.V. is bringing unbiased screening to the bispecifics space. The biotech is betting the approach can discover bispecific antibodies with novel activity against known...
BioCentury | Aug 25, 2016
Distillery Therapeutics

Therapeutics: Histidine-rich glycoprotein (HRG; HPRG)

...HRG could help treat sepsis and sepsis-induced acute respiratory distress syndrome (ARDS). Plasma levels of HRG...
...model of the disease than in healthy volunteers or mice. In the mouse model, human HRG...
...steps could include identifying and testing small molecules that promote HRG expression. TARGET/MARKER/PATHWAY: Histidine-rich glycoprotein (HRG; HPRG...
Items per page:
1 - 10 of 17